Biosimilars (remicade,humira,enbrel)

(2:53)

FDA Approves of Biosimilar to Infliximab – IBD in the News

(6:18)

Biosimilars Part 2: Regulatory and Current Status

(13:25)

Samsung Bioepis Receives First FDA Drug Approval for Remicade Biosimilar

(2:24)

Biosimilars and Inflammatory Bowel Disease

(4:4)

Biosimilars and Biologics

(38:15)

FDA approves Celltrion’s biosimilar drug Remsima for sales in U.S.

(2:12)

Dr Jeremy Schafer Discusses the Importance of Immunogenicity of Biosimilars

(1:2)

The Current Landscape of Biosimilars in IBD

(16:44)

FDA approves Celltrion’s biosimilar drug Remsima for sales in U.S.

(1:56)

Comment: Immunogenicity of biosimilars

(1:28)

Infliximab (Remicade, Inflectra, Renflexis, Remsima) - IBD treatments explained by the experts

(9:41)

Why IBD Patients Should Know About Biosimilars

(39:51)

What to Know Before Switching from Biologics to Biosimilars?

(2:23)

FDA: Celltrion’s Remicade Biosimilar “Highly Similar” To Branded Drug

(2:25)

Differences between Biologics, Biosimilars and Generic Medications

(3:57)

What Remicade Infusions are Like (Inflectra Biosimilar)

(5:40)

Biosimilars vs. Biologics: Side Effects, Safety and Effectiveness

(4:42)

Webinar: Biosimilars Development in Autoimmune and Inflammatory Diseases

(58:33)

Can Originator Infliximab Pricing Remain Competitive in Treating Inflammatory Bowel Disease?

(15:)